Literature DB >> 9580051

Receptor-mediated endocytosis in kidney proximal tubules: recent advances and hypothesis.

V Marshansky1, S Bourgoin, I Londoño, M Bendayan, B Maranda, P Vinay.   

Abstract

Preparation of kidney proximal tubules in suspension allows the study of receptor-mediated endocytosis, protein reabsorption, and traffic of endosomal vesicles. The study of tubular protein transport in vitro coupled with that of the function of endosomal preparation offers a unique opportunity to investigate a receptor-mediated endocytosis pathway under physiological and pathological conditions. We assume that receptor-mediated endocytosis of albumin in kidney proximal tubules in situ and in vitro can be regulated, on the one hand, by the components of the acidification machinery (V-type H+-ATPase, Cl(-)-channel and Na+/H+-exchanger), giving rise to formation and dissipation of a proton gradient in endosomal vesicles, and, on the other hand, by small GTPases of the ADP-ribosylation factor (Arf)-family. In this paper we thus analyze the recent advances of the studies of cellular and molecular mechanisms underlying the identification, localization, and function of the acidification machinery (V-type H+-ATPase, Cl(-)-channel) as well as Arf-family small GTPases and phospholipase D in the endocytotic pathway of kidney proximal tubules. Also, we explore the possible functional interaction between the acidification machinery and Arf-family small GTPases. Finally, we propose the hypothesis of the regulation of translocation of Arf-family small GTPases by an endosomal acidification process and its role during receptor-mediated endocytosis in kidney proximal tubules. The results of this study will not only enhance our understanding of the receptor-mediated endocytosis pathway in kidney proximal tubules under physiological conditions but will also have important implications with respect to the functional consequences under some pathological circumstances. Furthermore, it may suggest novel targets and approaches in the prevention and treatment of various diseases (cystic fibrosis, Dent's disease, diabetes and autosomal dominant polycystic kidney disease).

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9580051     DOI: 10.1002/elps.1150181423

Source DB:  PubMed          Journal:  Electrophoresis        ISSN: 0173-0835            Impact factor:   3.535


  6 in total

1.  Inhibition of Na+-H+ exchanger-3 interferes with apical receptor-mediated endocytosis via vesicle fusion.

Authors:  M Gekle; R Freudinger; S Mildenberger
Journal:  J Physiol       Date:  2001-03-15       Impact factor: 5.182

2.  Inhibition of Na+-H+ exchange impairs receptor-mediated albumin endocytosis in renal proximal tubule-derived epithelial cells from opossum.

Authors:  M Gekle; K Drumm; S Mildenberger; R Freudinger; B Gassner; S Silbernagl
Journal:  J Physiol       Date:  1999-11-01       Impact factor: 5.182

3.  Transforming growth factor-beta1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells.

Authors:  Michael Gekle; Petra Knaus; Rikke Nielsen; Sigrid Mildenberger; Ruth Freudinger; Verena Wohlfarth; Christoph Sauvant; Erik I Christensen
Journal:  J Physiol       Date:  2003-10-15       Impact factor: 5.182

4.  V-ATPase blockade reduces renal gluconeogenesis and improves insulin secretion in type 2 diabetic rats.

Authors:  Jun Hirao; Akihiro Tojo; Saaya Hatakeyama; Hiroshi Satonaka; Toshihiko Ishimitsu
Journal:  Hypertens Res       Date:  2020-05-08       Impact factor: 3.872

5.  Expanding the phenotype of proteinuria in Dent disease. A case series.

Authors:  Monica T Cramer; Jennifer R Charlton; Agnes B Fogo; Sahar A Fathallah-Shaykh; David J Askenazi; Lisa M Guay-Woodford
Journal:  Pediatr Nephrol       Date:  2014-05-09       Impact factor: 3.714

6.  H+-ATPase blockade reduced renal gluconeogenesis and plasma glucose in a diabetic rat model.

Authors:  Akihiro Tojo; Saaya Hatakeyama; Masaomi Nangaku; Toshihiko Ishimitsu
Journal:  Med Mol Morphol       Date:  2018-01-09       Impact factor: 2.309

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.